Enzychem Lifesciences Corporation (183490.KQ)
KRW 1147.0
(-1.12%)
KRW 1147.0
(-1.12%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 14.94 Billion KRW | 52.6% |
| 2022 | 9.79 Billion KRW | 17.22% |
| 2021 | 8.35 Billion KRW | -8.96% |
| 2020 | 9.17 Billion KRW | 16.97% |
| 2019 | 7.84 Billion KRW | 10.09% |
| 2018 | 7.12 Billion KRW | 2.42% |
| 2017 | 6.95 Billion KRW | 19.74% |
| 2016 | 5.81 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 15.34 Billion KRW | 2.67% |
| 2024 Q2 | 15.19 Billion KRW | -0.99% |
| 2023 Q1 | 12.61 Billion KRW | 28.82% |
| 2023 FY | 14.94 Billion KRW | 52.6% |
| 2023 Q3 | 14.4 Billion KRW | 4.57% |
| 2023 Q2 | 13.77 Billion KRW | 9.15% |
| 2023 Q4 | 14.94 Billion KRW | 3.78% |
| 2022 Q2 | 10.09 Billion KRW | 16.97% |
| 2022 Q1 | 8.63 Billion KRW | 3.3% |
| 2022 Q4 | 9.79 Billion KRW | -1.26% |
| 2022 FY | 9.79 Billion KRW | 17.22% |
| 2022 Q3 | 9.91 Billion KRW | -1.74% |
| 2021 Q4 | 8.35 Billion KRW | 10.34% |
| 2021 Q2 | 7.99 Billion KRW | -20.21% |
| 2021 Q3 | 7.57 Billion KRW | -5.32% |
| 2021 Q1 | 10.02 Billion KRW | 9.21% |
| 2021 FY | 8.35 Billion KRW | -8.96% |
| 2020 Q4 | 9.17 Billion KRW | -4.21% |
| 2020 FY | 9.17 Billion KRW | 16.97% |
| 2020 Q1 | 7.35 Billion KRW | -6.28% |
| 2020 Q3 | 9.58 Billion KRW | 22.78% |
| 2020 Q2 | 7.8 Billion KRW | 6.11% |
| 2019 Q4 | 7.84 Billion KRW | -1.53% |
| 2019 FY | 7.84 Billion KRW | 10.09% |
| 2019 Q1 | 8.26 Billion KRW | 16.02% |
| 2019 Q3 | 7.96 Billion KRW | 6.93% |
| 2019 Q2 | 7.45 Billion KRW | -9.89% |
| 2018 Q1 | - KRW | -100.0% |
| 2018 FY | 7.12 Billion KRW | 2.42% |
| 2018 Q2 | 7.14 Billion KRW | 0.0% |
| 2018 Q3 | 8.77 Billion KRW | 22.77% |
| 2018 Q4 | 7.12 Billion KRW | -18.79% |
| 2017 FY | 6.95 Billion KRW | 19.74% |
| 2017 Q4 | 6.95 Billion KRW | 0.0% |
| 2016 FY | 5.81 Billion KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 20.85 Billion KRW | 28.345% |
| CMG Pharmaceutical Co., Ltd. | 15.87 Billion KRW | 5.857% |
| Celltrion Pharm, Inc. | 100.42 Billion KRW | 85.117% |
| Huons Global Co., Ltd. | 121.81 Billion KRW | 87.731% |
| DongKook Pharmaceutical Co., Ltd. | 138.34 Billion KRW | 89.197% |
| Humedix Co., Ltd. | 28.62 Billion KRW | 47.788% |
| Boditech Med Inc. | 31.6 Billion KRW | 52.707% |
| EuBiologics Co., Ltd. | 13.34 Billion KRW | -12.025% |
| FutureChem Co.,Ltd | 1.37 Billion KRW | -987.363% |
| Huons Co., Ltd. | 76.59 Billion KRW | 80.488% |
| BNC Korea Co., Ltd. | 11.39 Billion KRW | -31.179% |
| AptaBio Therapeutics Inc. | - KRW | -Infinity% |